Table 1 Patient characteristics based on COVID-19 severity
Study | Country (City) | Study design | Study period | Non-severe COVID-19 | Severe COVID-19 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | BMI (kg/m2) | Dyslipidemia (n) | Non-dyslipidemia (n) | Age (years) | BMI (kg/m2) | Dyslipidemia (n) | Non-dyslipidemia (n) | ||||
Maeda [8] | USA (New York) | Cohort | Mar13–31, 2020 | 65 [51–77] | 28.9 [24.7, 2.3] | 64 | 103 | 67 [58–76] | 27.2 [24.1, 31.8] | 28 | 29 |
Ferguson [9] | USA (California) | Cohort | Mar13–Apr11, 2020 | 61.7 [46.6–72.9] | NA | 17 | 34 | 57.6 [42.2–70.1] | NA | 8 | 13 |
Zhang [10] | China (Wuhan) | Cohort | Jan16–Feb3, 2020 | 51.5 (26–78) | NA | 5 | 77 | 64 (25–87) | NA | 2 | 56 |
To [11] | China (Hong Kong) | Cohort | Jan22–Feb12, 2020 | 56 (37–75) | NA | 0 | 13 | 66 (39–75) | NA | 2 | 8 |
Rastrelli [12] | Italy (Mantua) | Cohort | NA | 63.0 [55.0–66.5] | NA | 5 | 16 | NA | NA | 3 | 7 |
Almazeedi [13] | Kuwait | Cohort | Feb24–Apr 20, 2020 | 37.1 ± 16 | 26.8 ± 7.7 | 58 | 996 | 54.8 ± 11 | 29.0 ± 5.1 | 7 | 35 |
Chen [14] | China (Zhejiang) | Cohort | Jan1–Mar11, 2020 | 45.3 ± 13.6 | 23.20 [21.66–25.71] | 0 | 102 | 52.8 ± 15.5 | 24.78 [23.07–26.96] | 1 | 42 |
Jurado [15] | Spain | Cohort | Second half of March 2020 | NA | NA | 105 | 286 | NA | NA | 54 | 108 |
Wu [16] | China (Wuhan) | Cohort | Dec23, 2019–Feb13, 2020 | 43.0 [33.0–61.0] | NA | 11 | 217 | 62.0 [52.5–71.5] | NA | 5 | 66 |
Urra [17] | Spain | Case- control | Mar1–Apr15, 2020 | 57.89 ± 13.1 | NA | 54 | 91 | 65.64 ± 14.1 | NA | 5 | 22 |
Gidari [18] | Italy (Perugia) | Cohort | Mar1–Apr20, 2020 | 63 ± 17 | NA | 8 | 33 | 65 ± 9 | NA | 2 | 25 |
Zhang [19] | China (Beijing) | Cohort | Jan–Feb 2020 | 45.34 ± 15.25 | NA | 2 | 54 | 64.75 ± 14.76 | NA | 1 | 23 |
de la Rica [20] | Spain (Mallorca) | Cohort | as of Mar 31, 2020 | 66.30 ± 14.90 | NA | 16 | 11 | 65.57 ± 12.87 | NA | 13 | 7 |
Simonnet [21] | France | Cohort | Feb27–Apr5, 2020 | 60 [50–72] | 27 [25.3–30.8] | 10 | 29 | 60 [51–69] | 31.1 [27.3–37.5] | 24 | 61 |
Petrilli [22] | USA (New York) | Cohort | Mar1–Apr8, 2020 | 60 [48–71] | NA | 692 | 1047 | 68 [58–78] | NA | 465 | 525 |
Li [23] | China (Wuhan) | Case- control | NA | 51.45 ± 15.08 | NA | 48 | 376 | 61.54 ± 13.36 | NA | 8 | 91 |
Chang [24] | South Korea (Daegu) | Cohort | Feb28–Mar 31, 2020 | 36.47 ± 14.04 | NA | 4 | 194 | 54.08 ± 11.98 | NA | 2 | 11 |
Kong [25] | China (Wuhan) | Cohort | Jan27–Mar9, 2020 | 53.2 ± 15.6 | NA | 2 | 121 | 67.9 ± 12.3 | NA | 3 | 84 |
Lodigiani [26] | Italy (Milan) | Cohort | Feb13–Apr10, 2020 | 68 [55–77] | NA | 69 | 258 | 61 [55–69] | NA | 7 | 54 |